On January 8th, Academician Max Cynader, founder of the Brain Research Center at the University of British Columbia (UBC) in Canada, and his team were invited by Researcher Xie Yongmei to visit the State Key Laboratory of Biotherapy at West China Hospital of Sichuan University. On behalf of the team of the laboratory, Professor Chen Lijuan extended a warm welcome to the arrival of Academician Max Cynader and discussed related cooperation with Max.
Left: Xie Yongmei Right: Dr. Max Cynader
As a Fellow of The Academy of Science of the Royal Society of Canada, Max Cynader is the Director of Research Centre in University of British Columbia (UBC)，Vancouver Coastal Health Research Institute and Djavad Mowafaghian Centre for Brain Health. He was hired as chairman of Canada Brain Research and Development Center at UBC for his outstanding contributions. He is also a professor of the Department of Ophthalmology & Visual Sciences at UBC. He was awarded the Canada Medal of Governor General (CM) and the British Columbia Medal (OBC). He is a Fellow of the Canadian Academy of Health Sciences (FCAHS) and the Principal Investigator in Canadian Network of Excellence in Stroke, committed to applied basic research on stroke and neuro degenerative diseases. Up to now, multiple drugs under his development have entered into different stages of clinical trials.
Based on his own work and research experience, Academician Cynader presented an academic theme report entitled "Primary Peptides: Replacing antisense, and targeting protein-protein interactions using Peptide Therapeutics", detailing the screening via Peptide array technology to block protein-protein interaction of small molecule peptide and the process of successful transformation into clinical trials. Academician Cynader carried out extensive and in-depth academic exchanges with teachers and students on the spot, answered questions raised by the audience, and shared his opinions. His views opened up the audiences’ horizons of new drug research.
As an internationally renowned brain science expert, Academician Cynader founded the UBC Brain Research Center, which is one of the top global brain science research institutions with extensive influence in the international brain science community. Sichuan University also has an advanced research platform-National Science and Technology Infrastructure for Translational Medicine, with considerable strength in basic research accumulation and clinical application research. After the academic report, Academician Cynader had in-depth communication with several professors in the laboratory. He hoped to combine the advantages of both parties to carry out comprehensive and in-depth cooperation on the current bottleneck problems of peptide drugs, such as target selectivity, short half-life, and oral drug difficulties. The joint cooperation could promote basic research, pharmaceutical research and clinical application of peptide drugs, and make greater contributions to the development of human health.
